DLX-105 is a human monoclonal antibody (mAb) that targets TNFSF2/TNFa. It reduces epidermal thickness and the expression of K16 and Ki67 in the skin. Additionally, DLX-105 downregulates mRNA levels of IL-17, TNF-alpha, IL-23p19, IL-12p40, and IFN-gamma. This compound is useful for psoriasis research.
Target:
IFNAR|||Interleukin|||TNF
* VAT and and shipping costs not included. Errors and price changes excepted
